Trial Profile
A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenoid cystic carcinoma
- Focus Therapeutic Use
- 26 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 26 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 26 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.